Marbocyl P 5mg

Marbocyl P 5mg

buy Marbocyl P 5mg

In dogs:

  • Curative treatment of superficial and deep pyoderma,
  • Curative treatment of urinary tract infections due to Proteus mirabilis and Escherichia coli, associated or not with prostatits and/or epididymitis,
  • Curative treatment of respiratory tract infections.

In cats :

  • Curative treatment of cutaneous and subcutaneous infections (wounds, abscesses, phlegmons)
  • Curative treatment of the superior respiratory tract infections.

Dosage and administration:

2 mg of marbofloxacin per kg of b.w. once a day.


5, 20 and 80 mg

10, 100 or 250 tablets box

Marbocyl P 5mg


Marbofloxacin is a bactericidal anti-infectious synthesis belonging to the fluoroquinolones group.
It acts by inhibition of DNA-gyrase. Its very broad spectrum is directed towards Gram positive
(especially Staphylococcus and Streptococcus), Gram negative bacteria (Escherichia Coli,
Salmonella Aertricke, Citrobacter freundii, Aerobacter cloacae, Serratia marcescens, Morganella
morganii, Proteus sp, Klebsiella sp, Shigella sp, Pasteurella sp, Haemophilus sp, Moraxella sp,
Pseudomonas sp, Brucella canis) and Mycoplasma.
After oral use at the recommended dose of 2 mg/kg in the cat and dog, Marbofloxacin is rapidly
absorbed and reaches maximal plasmatic concentrations of 1.5 µg/ml in 2 hours approximately.
The bioavailability of Marbofloxacin is close to 100 %. It is slightly related to plasmatic proteins (<
than 10 %) and is widely distributed in the entire organism. In the majority of tissues (liver,
kidney, skin, lungs, bladder and digestive tract), tissular concentrations are higher than those of
plasma. Marbofloxacin is slowly eliminated (half-life of elimination : 14 hours in the dog and 10
hours in the cat) and mainly in active form in the urines (2/3) and faeces (1/3).
Marbofloxacin is well tolerated in growing medium sized-dogs until doses reaching 4 mg/kg/day
for 13 weeks. However, it is not recommended to use it in giant breeds dogs under 1 year.
Side effects
Minor side effects may occur during treatment, such as vomiting, softening of saddles, alteration
of the thirst, transitory hyperactivity. These signs disappear spontaneously and it is not
necessary to stop treatment.
Use during pregnancy and lactation
Studies in animals of laboratory (rat, rabbit) have not produced any evidence of a teratogenic,
foetotoxic or maternotoxic effect of Marbofloxacin at the dose used in therapeutics.
Harmlessness of the product in queens during pregnancy and suckling has not been shown. The
use of this product in pregnant or suckling females should be avoided or only accordingly to the
benefit/risk assessment by the responsible veterinarian.
In the case of concomitant oral administration of cations (aluminium, calcium, iron, magnesium),
the bioavailability of Marbofloxacin can be reduced. It is recommended to lower the dose of
Theophylline in the case of concomitant administration.
Special precautions for storage
Do not store above 25°C.

Marbocyl P 5mg

Leave a Reply

Your email address will not be published. Required fields are marked *